Your browser doesn't support javascript.
loading
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza, Afsheen; Mohsen, Reyad; Kanbour, Aladdin; Zar Gul, Abdul Rehman; Philip, Anite; Vijayakumar, Suma; Hydrose, Shereena; Prabhu, Kirti S; Al-Suwaidi, Aisha Khamis; Inchakalody, Varghese Philipose; Merhi, Maysaloun; Abo El-Ella, Dina M; Tauro, Melissa Annrose; Akbar, Shayista; Al-Bozom, Issam; Abualainin, Wafa; Al-Abdulla, Rajaa; Sirriya, Shaza Abu; Hassnad, Suparna; Uddin, Shahab; Mohamed Ibrahim, Mohamed Izham; Al Homsi, Ussama; Demime, Said.
Affiliation
  • Raza A; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Mohsen R; Translational Cancer Research Facility, Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Kanbour A; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Zar Gul AR; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Philip A; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Vijayakumar S; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Hydrose S; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Prabhu KS; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Al-Suwaidi AK; Translational Cancer Research Facility, Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Inchakalody VP; Translational Research Institute (TRI), Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Merhi M; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Abo El-Ella DM; Translational Cancer Research Facility, Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Tauro MA; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Akbar S; Translational Cancer Research Facility, Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Al-Bozom I; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Abualainin W; Translational Cancer Research Facility, Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Al-Abdulla R; Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Sirriya SA; Translational Cancer Research Facility, Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Hassnad S; Department of Human Genetics, Sidra Medical and Research Center, Doha, Qatar.
  • Uddin S; College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
  • Mohamed Ibrahim MI; Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
  • Al Homsi U; Diagnostic Genomic Division , Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
  • Demime S; Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.
Front Immunol ; 14: 1157100, 2023.
Article in En | MEDLINE | ID: mdl-37256148
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Qatar
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Qatar